These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30376551)

  • 1. Favorable Outcome of an Exclusively Posttransplant Prophylactic Strategy After Heart Transplantation in Recipients With High Immunological Risk.
    Coutance G; d'Orio V; Belin L; Bréchot N; Saheb S; Lebreton G; Bouglé A; Rouvier P; Gautreau C; Ouldammar S; Chamillard X; Huot M; Amour J; Combes A; Leprince P; Varnous S
    Transplantation; 2019 Jul; 103(7):1439-1449. PubMed ID: 30376551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
    Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
    Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
    Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
    Kimball PM; McDougan FA; King A
    Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA: The Necker High-Risk Transplant Program.
    Amrouche L; Aubert O; Suberbielle C; Rabant M; Van Huyen JD; Martinez F; Sberro-Soussan R; Scemla A; Tinel C; Snanoudj R; Zuber J; Cavalcanti R; Timsit MO; Lamhaut L; Anglicheau D; Loupy A; Legendre C
    Transplantation; 2017 Oct; 101(10):2440-2448. PubMed ID: 28114171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.
    Loupy A; Suberbielle-Boissel C; Zuber J; Anglicheau D; Timsit MO; Martinez F; Thervet E; Bruneval P; Charron D; Hill GS; Nochy D; Legendre C
    Transplantation; 2010 Jun; 89(11):1403-10. PubMed ID: 20386362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Immunoglobulins Alone for the Desensitization of Lung Transplant Recipients with Preformed Donor Specific Antibodies and Negative Flow Cytometry Crossmatch.
    Abdulqawi R; Alawwami M; Aldosari O; Aldosari Z; Alhuqbani M; Saleh RA; Esendagli D; Aldakhil H; De Vol EB; Alkattan K; Marquez KAH; Saleh W; Sandoqa S; Al-Mutairy EA
    Clin Transplant; 2024 Jul; 38(7):e15374. PubMed ID: 38979724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients.
    Kimball PM; King A
    Clin Transpl; 2011; ():369-72. PubMed ID: 22755433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Criteria and Definitions: Outcome of a Standardized Antibody-Mediated Rejection Protocol with a Diagnostic Schema Different from the Banff 2009 Criteria.
    Rendulic T; Ramon DS; Killen PD; Samaniego-Picota M; Park JM
    Clin Transpl; 2014; ():179-87. PubMed ID: 26281143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of recipients of human leukocyte antigen incompatible kidney transplants who underwent desensitization at King Fahad Specialist Hospital, Dammam, Saudi Arabia.
    Idris MA; Hossain A; Muntasir MA; Marmi A; Aldajani AA; Aljamaan YM; Akhtar M; Housawi A
    Saudi J Kidney Dis Transpl; 2017; 28(3):499-506. PubMed ID: 28540885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Sex in the Efficacy of Perioperative Desensitization Procedures in Heart Transplantation: A Retrospective Cohort Study.
    Nguyen LS; Salem JE; Bories MC; Coutance G; Amour J; Bougle A; Suberbielle C; Kheav VD; Carmagnat M; Rouvier P; Kirsch M; Varnous S; Leprince P; Saheb S
    Front Immunol; 2021; 12():659303. PubMed ID: 34305891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
    Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
    Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.